At meeting held on 19 May 2015
Glenmark Pharmaceuticals announced that the Preferential Issue Committee of the Board of Directors of the Company, at its Meeting held on 19 May 2015 allotted 1,08,00,000 Equity Shares of the face value of Re. 1/- each at a price of Rs. 875 per equity share to Aranda Investments (Mauritius), on preferential basis in terms of Chapter VII of SEBI (ICDR) Regulations and the applicable sections of the Companies Act, 2013.Powered by Capital Market - Live News
